BACKGROUND To assess the effectiveness of Shugan Jieyu capsules on peripheral blood miR-124,miR-132,and brain-derived neurotrophic factor(BDNF)levels in patients with mild to moderate depression following coronary art...BACKGROUND To assess the effectiveness of Shugan Jieyu capsules on peripheral blood miR-124,miR-132,and brain-derived neurotrophic factor(BDNF)levels in patients with mild to moderate depression following coronary artery intervention[percuta-neous coronary intervention(PCI)]for coronary heart disease.Patients with mild-to-moderate depression of the liver-qi stagnation type after PCI for coronary heart disease at the 305th Hospital of the People’s Liberation Army were enrolled from June 2022 to November 2023 and randomly assigned to two groups:Experimental(treated with Shugan Jieyu capsules)and control(tr-eated with escitalopram oxalate tablets).This study compared the antidepressant effects of these treatments using 17-item Hamilton Rating Scale for Depression(HAMD-17)scores,metabolic equivalents,low-density lipoprotein cholesterol,BDNF,high-sensitivity C-reactive protein levels,miR-124 and miR-132 levels,distribution of immune-related lymphocyte subsets,and traditional Chinese me-dicine syndrome scores before and after 6 weeks of treatment.RESULTS No significant difference was observed in any index between the two groups before treatment(P>0.05).After treatment,the total efficacy rates were 93.33%and 90.00%in the experimental and control groups,respectively.Experimental group had significantly lower scores for the main and secondary syndromes compared to the control group(P<0.05).No significant difference was observed in the metabolic equivalents between the two groups be-fore and after treatment(P>0.05).The levels of low-density lipoprotein cholesterol,high-sensitivity C-reactive pro-tein,and miR-132 were significantly lower,whereas those of miR-124,BDNF,CD3+T lymphocytes,CD3+CD4+T helper lymphocytes,and CD3+CD4+/CD3+CD8+cells were significantly higher in the experimental group com-pared to the control group(P<0.05).The incidence of adverse reactions during experimental group was signi-ficantly lower than that in control group(P<0.05).CONCLUSION Shugan Jieyu capsules have good efficacy in patients with mild-to-moderate depression after PCI,and its me-chanism may contribute to the regulation of miR-124,miR-132,BDNF levels,and lymphoid immune cells.展开更多
Shuganjieyu capsule has been approved for clinical treatment by the State Food and Drug Ad-ministration of China since 2008. In the clinic, Shuganjieyu capsule is often used to treat mild to moderate depression. In th...Shuganjieyu capsule has been approved for clinical treatment by the State Food and Drug Ad-ministration of China since 2008. In the clinic, Shuganjieyu capsule is often used to treat mild to moderate depression. In the rat model of depression established in this study, Shuganjieyu capsule was administered intragastrically daily before stress. Behavioral results conifrmed that depressive symptoms lessened after treatment with high-dose （150 mg/kg） Shuganjieyu capsule. Immunohistochemistry results showed that high-dose Shuganjieyu capsule signiifcantly increased phosphorylation levels of phosphorylation cyclic adenosine monophosphate response element binding protein and brain-derived neurotrophic factor expression in the medial prefrontal cortex and hippocampal CA3 area. Overall, our results suggest that in rats, Shuganjieyu capsule effec-tively reverses depressive-like behaviors by increasing expression levels of neurotrophic factors in the brain.展开更多
目的：观察舒肝解郁胶囊治疗伴抑郁状态的老年轻度认知功能障碍的临床疗效。方法将120例患者随机分为治疗组和对照组各60例，治疗组给予舒肝解郁胶囊，对照组给予盐酸氟西汀。观察治疗前后患者自觉症状评分、汉密尔顿抑郁量表（ HAMD）...目的：观察舒肝解郁胶囊治疗伴抑郁状态的老年轻度认知功能障碍的临床疗效。方法将120例患者随机分为治疗组和对照组各60例，治疗组给予舒肝解郁胶囊，对照组给予盐酸氟西汀。观察治疗前后患者自觉症状评分、汉密尔顿抑郁量表（ HAMD）、简易精神状况检查表（ MMSE）得分变化及临床疗效。结果治疗后治疗组自觉症状均明显改善（ P ＜0．05），而对照组仅失眠、多梦、乏力、心悸改善（ P ＜0．05），且治疗组健忘、眩晕、耳鸣改善优于对照组（ P ＜0．05）；2组治疗后HAMD总分降低（ P ＜0．05），其中治疗组以焦虑／躯体性症状、认识障碍和睡眠障碍改善最为明显（ P ＜0．05），而认识障碍改善优于对照组（ P ＜0．05）；治疗组治疗后MMSE总分升高（ P ＜0．05），尤以注意力和计算力、即时回忆力、延迟回忆力改善最为明显（ P ＜0．05），而对照组仅注意力和计算力改善（ P ＜0．05）。治疗组总有效率为78．33％，优于对照组的60．00％（χ2＝4．728， P ＜0．05）。治疗组不良反应发生率为13．33％，低于对照组35．00％（χ2＝7．685， P ＜0．05）。结论舒肝解郁胶囊可作为伴抑郁状态的老年轻度认知功能障碍的长期治疗用药。展开更多
基金the 305 Hospital Independent Scientific Research Fund,2024,No.24ZZJJLW-022.
文摘BACKGROUND To assess the effectiveness of Shugan Jieyu capsules on peripheral blood miR-124,miR-132,and brain-derived neurotrophic factor(BDNF)levels in patients with mild to moderate depression following coronary artery intervention[percuta-neous coronary intervention(PCI)]for coronary heart disease.Patients with mild-to-moderate depression of the liver-qi stagnation type after PCI for coronary heart disease at the 305th Hospital of the People’s Liberation Army were enrolled from June 2022 to November 2023 and randomly assigned to two groups:Experimental(treated with Shugan Jieyu capsules)and control(tr-eated with escitalopram oxalate tablets).This study compared the antidepressant effects of these treatments using 17-item Hamilton Rating Scale for Depression(HAMD-17)scores,metabolic equivalents,low-density lipoprotein cholesterol,BDNF,high-sensitivity C-reactive protein levels,miR-124 and miR-132 levels,distribution of immune-related lymphocyte subsets,and traditional Chinese me-dicine syndrome scores before and after 6 weeks of treatment.RESULTS No significant difference was observed in any index between the two groups before treatment(P>0.05).After treatment,the total efficacy rates were 93.33%and 90.00%in the experimental and control groups,respectively.Experimental group had significantly lower scores for the main and secondary syndromes compared to the control group(P<0.05).No significant difference was observed in the metabolic equivalents between the two groups be-fore and after treatment(P>0.05).The levels of low-density lipoprotein cholesterol,high-sensitivity C-reactive pro-tein,and miR-132 were significantly lower,whereas those of miR-124,BDNF,CD3+T lymphocytes,CD3+CD4+T helper lymphocytes,and CD3+CD4+/CD3+CD8+cells were significantly higher in the experimental group com-pared to the control group(P<0.05).The incidence of adverse reactions during experimental group was signi-ficantly lower than that in control group(P<0.05).CONCLUSION Shugan Jieyu capsules have good efficacy in patients with mild-to-moderate depression after PCI,and its me-chanism may contribute to the regulation of miR-124,miR-132,BDNF levels,and lymphoid immune cells.
基金supported by the National Natural Science Foundation of China,No.81071093,81171268
文摘Shuganjieyu capsule has been approved for clinical treatment by the State Food and Drug Ad-ministration of China since 2008. In the clinic, Shuganjieyu capsule is often used to treat mild to moderate depression. In the rat model of depression established in this study, Shuganjieyu capsule was administered intragastrically daily before stress. Behavioral results conifrmed that depressive symptoms lessened after treatment with high-dose （150 mg/kg） Shuganjieyu capsule. Immunohistochemistry results showed that high-dose Shuganjieyu capsule signiifcantly increased phosphorylation levels of phosphorylation cyclic adenosine monophosphate response element binding protein and brain-derived neurotrophic factor expression in the medial prefrontal cortex and hippocampal CA3 area. Overall, our results suggest that in rats, Shuganjieyu capsule effec-tively reverses depressive-like behaviors by increasing expression levels of neurotrophic factors in the brain.
文摘目的：观察舒肝解郁胶囊治疗伴抑郁状态的老年轻度认知功能障碍的临床疗效。方法将120例患者随机分为治疗组和对照组各60例，治疗组给予舒肝解郁胶囊，对照组给予盐酸氟西汀。观察治疗前后患者自觉症状评分、汉密尔顿抑郁量表（ HAMD）、简易精神状况检查表（ MMSE）得分变化及临床疗效。结果治疗后治疗组自觉症状均明显改善（ P ＜0．05），而对照组仅失眠、多梦、乏力、心悸改善（ P ＜0．05），且治疗组健忘、眩晕、耳鸣改善优于对照组（ P ＜0．05）；2组治疗后HAMD总分降低（ P ＜0．05），其中治疗组以焦虑／躯体性症状、认识障碍和睡眠障碍改善最为明显（ P ＜0．05），而认识障碍改善优于对照组（ P ＜0．05）；治疗组治疗后MMSE总分升高（ P ＜0．05），尤以注意力和计算力、即时回忆力、延迟回忆力改善最为明显（ P ＜0．05），而对照组仅注意力和计算力改善（ P ＜0．05）。治疗组总有效率为78．33％，优于对照组的60．00％（χ2＝4．728， P ＜0．05）。治疗组不良反应发生率为13．33％，低于对照组35．00％（χ2＝7．685， P ＜0．05）。结论舒肝解郁胶囊可作为伴抑郁状态的老年轻度认知功能障碍的长期治疗用药。
